Department of Pulmonology, Division of Allergy, Hôpital Arnaud de Villeneuve, University Hospital of Montpellier, University of Montpellier, Montpellier, France,
UMR-S 1136 INSERM-Sorbonne Université, Equipe EPAR - IPLESP, Paris, France,
Int Arch Allergy Immunol. 2021;182(3):182-189. doi: 10.1159/000510592. Epub 2020 Sep 22.
Among allergic rhinitis (AR) symptoms, nasal obstruction particularly affects the quality of life. Antihistamines and intranasal corticosteroids are the most frequently prescribed symptomatic drugs, but their efficacy is often incomplete. Essential oils (EO) have shown an anti-inflammatory effect and potential in treating patients with AR. The aim of this study was to evaluate the effectiveness of a hypertonic EO-based nasal spray on perennial AR (PAR) symptoms.
This prospective, open-label, non-randomized, multicentric trial included 43 patients with PAR sensitized to mites, not controlled for more than a year. All were treated with Puressentiel® Respiratory-Decongestant Nasal Spray for 30 days. Their usual treatment remained unchanged during the study period. Before and after treatment, each participant filled out a rhinitis questionnaire, the Allergic Rhinitis Control Test (ARCT). A nasal inspiratory peak flow (NIPF) was performed.
The mean ARCT was 16.4 and 20.5 at D0 and D30, respectively (p < 0.001); the mean increase between D0 and D30 was 4.1 (p < 0.001). The proportion of patients with controlled rhinitis after 30 days of treatment was 69.8 versus 14% before treatment (p < 0.001). The mean NIPF was 86.5 L/min and 105.1 L/min at D0 and D30, respectively (p < 0.001); the mean increase between D0 and D30 was 18.5 L/min.
A hypertonic EO-based nasal spray could be a new and natural option in the management of PAR. It could also be used as an add-on therapy when nasal symptoms are not fully controlled.
在过敏性鼻炎（AR）症状中，鼻塞特别影响生活质量。抗组胺药和鼻内皮质类固醇是最常开的对症药物，但疗效往往不完整。精油（EO）已显示出抗炎作用，并有可能治疗 AR 患者。本研究旨在评估基于高渗 EO 的鼻喷雾剂对常年性 AR（PAR）症状的疗效。
这是一项前瞻性、开放标签、非随机、多中心试验，纳入了 43 名对螨虫过敏、未控制超过一年的 PAR 患者。所有患者均使用 Puressentiel® Respiratory-Decongestant Nasal Spray 治疗 30 天。在研究期间，他们的常规治疗保持不变。在治疗前后，每位参与者填写一份鼻炎问卷，即过敏性鼻炎控制测试（ARCT）。还进行了鼻吸气峰流速（NIPF）测试。
ARCT 均值分别为治疗前的 16.4 和治疗后的 20.5（p<0.001）；治疗后与治疗前相比平均增加了 4.1（p<0.001）。治疗 30 天后，控制良好的鼻炎患者比例从治疗前的 14%增加到了 69.8%（p<0.001）。NIPF 均值分别为治疗前的 86.5 L/min 和治疗后的 105.1 L/min（p<0.001）；治疗后与治疗前相比平均增加了 18.5 L/min。
高渗 EO 鼻喷雾剂可能是 PAR 管理的一种新的自然选择。当鼻症状未完全控制时，它也可以作为附加治疗。
